Fessas, P., Lee, H., Ikemizu, S., Janowitz, T. (April 2017) A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol, 44 (2). pp. 136-140. ISSN 0093-7754
Abstract
T-cell checkpoint inhibition has a profound impact on cancer care and the programmed cell death protein 1 (PD-1)-targeted antibodies nivolumab and pembrolizumab have been two of the lead molecules of this therapeutic revolution. Their clinical comparability is a highly relevant topic of discussion, but to a significant degree is a consequence of their molecular properties. Here we provide a molecular, preclinical, and early clinical comparison of the two antibodies, based on the available data and recent literature. We acknowledge the limitations of such comparisons, but suggest that based on the available data, differences in clinical trial outcomes between nivolumab and pembrolizumab are more likely drug-independent than drug-dependent.
| Item Type: | Paper |
|---|---|
| Subjects: | organs, tissues, organelles, cell types and functions > cell types and functions > cell types > T cells organs, tissues, organelles, cell types and functions > cell types and functions > cell types > T cells organs, tissues, organelles, cell types and functions > cell types and functions > cell types > T cells bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > antibodies diseases & disorders > cancer > drugs and therapies > Immunotherapy |
| CSHL Authors: | |
| Highlight: | Janowitz, Tobias |
| Depositing User: | Matthew Dunn |
| Date: | April 2017 |
| Date Deposited: | 10 Oct 2018 16:55 |
| Last Modified: | 10 Oct 2018 16:55 |
| PMCID: | PMC5612055 |
| Related URLs: | |
| URI: | https://repository.cshl.edu/id/eprint/37226 |
Actions (login required)
 |
Administrator's edit/view item |